1. Qu R#, Zhang Y#, Kim B#, Zeng G#, Wang P, Shaoyong W, Huang Y, Guo G, Chen Y, Wang P, Yang Q, Lu S, Zhou X, Weng J, Xu J, Lin J, Wang K, Ma Y, Takahashi S, Luo Y, Yu X, Krausz KW, Pang Y, Hong T, Zhang Z*, Fu W*, Gonzalez FJ*, and Sun L*. Microbial riboflavin inhibits ceramide synthase 3 to lower ceramide (d18:1/26:0) and delay colorectal cancer progression. Cell Metab, 2025. In press.
2. Chen B#, Sun L#, Zeng G#, Shen Z#, Wang K#, Yin L, Xu F, Wang P, Ding Y, Nie Q, Wu Q, Zhang Z, Xia J, Lin J, Luo Y, Cai J, Krausz KW, Zheng R, Xue Y, Zheng MH*, Li Y*, Yu C*, Gonzalez FJ*, Jiang C*. Gut bacteria alleviate smoking-related NASH by degrading gut nicotine, Nature, 2022, 61(7932): 562-568;高被引论文
3. Sun L#, Xie C#, Wang G#, Wu Y#, Wu Q, Wang X, Liu J, Deng Y, Xia J, Chen B, Zhang S, Yun C, Lian G, Zhang X, Zhang H, Bisson WH, Shi J, Gao X, Ge P, Liu C, Krausz KW, Nichols RG, Cai J, Rimal B, Patterson AD, Wang X, Gonzalez FJ, Jiang C*. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med, 2018, 24(12): 1919-1929 ; 高被引论文
4. Sun L#, Zhang Y#, Cai J, Rimal B, Rocha ER, Coleman JP, Zhang C, Nichols RG, Luo Y, Kim B, Chen Y, Krausz KW, Harris CC, Patterson AD, Zhang Z*, Takahashi S*, Gonzalez FJ*. Bile salt hydrolase in non-enterotoxigenic Bacteroides potentiates colorectal cancer. Nat Commun. 2023 Feb 10;14(1):755;
5. Wu Q#, Sun L#, Hu X#, Wang X, Xu F, Chen B, Liang X, Xia J, Wang P, Aibara D, Zhang S, Zeng G, Yun C, Yan Y, Zhu Y, Bustin M, Zhang S*, Gonzalez FJ*, Jiang C*. Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis. Journal of Clinical Investigation, 2021, 131(9): 0-e142865;